Dyslipidemia

Hypercholesterolemia is an important, modifiable cardiovascular risk factor. Besides the classical risk factors like LDL-C and apoB, other lipid risk factors like Lp(a), fasting and non-fasting triglycerides and HDL-C are important treatment targets for which different novel interventions are being developed. Modification of these risk factors represents an unmet clinical need and may help to reduce the well-known residual cardiovascular risk in clinical practice.

Recruiting a vast number of suitable dyslipidemia patients within a limited time frame at affordable costs, while maintaining high data quality and integrity can be a challenge. To overcome these hurdles, we have a dedicated expert team that is ready to provide you with the perfect tailor-made solution for your Dyslipidemia clinical trial.

Meet our scientific leaders for Dislipidemia clinical trials

Prof. Dr. Manuel Castro Cabezas is an internationally recognized expert in the field of lipids and associated diseases. He works as Scientific Officer for Julius Clinical and as a Senior consultant for internal medicine, endocrinology, and vascular medicine at the Franciscus Gasthuis Rotterdam. Prof. Castro Cabezas has participated in many clinical trials as PI and as initiator, in the fields of lipid management, diabetes and obesity.

Meet our scientific leaders for Dislipidemia clinical trials

Prof. Dr. Marco Alings is s a practicing cardiologist/electrophysiologist and Director of the cardiology training program at the Amphia Ziekenhuis, Breda, the Netherlands. Prof. Alings is a clinical trialist with a special interest in arrhythmias and stroke prevention, and has served as national coordinator for many large international multicenter studies.

Scientific networks

How we operate

Our Cardio Clinical network is based on solid and long collaborations with scientific experts in the field of cardiovascular diseases. The network consists of cardiologists and researchers from 833 sites in 20 countries, focusing on the development of novel therapies for Cardiovascular Diseases including lipid lowering cardiovascular intervention trials, stroke prevention and heart failure.